Clinical trials with VMO for melanoma.
Wallack
M K
MK
Department of Surgery, St. Vincent's Hospital, New York, New York.
Sivanandham
M
M
D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D016233:Immunotherapy, Active / Q000379:methods*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014616:Vaccinia virus
D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins